• Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

As a result, Musk found himself subjected to a series of drug tests.

“I had to have like random drug tests and stuff after that, to prove that I'm not like a drug addict…They drug tested me for everything, and randomly… I had like a whole year of random drug tests,” he elaborated.

In the U.S., the trajectory of cannabis legalization has seen considerable advancement at the state level. By the time Musk took that infamous puff on Rogan’s podcast in 2018, cannabis had already been legalized in multiple states. However, on the federal front, marijuana was — and still remains — categorized as a Schedule I substance under the Controlled Substances Act.

Nonetheless, this status might soon be evolving.

From Schedule I to Schedule III?

The U.S. Food and Drug Administration (FDA) has proposed that marijuana be reclassified from a Schedule I to Schedule III substance under the Controlled Substances Act, based on scientific and medical evaluations. This recommendation was recently released in documents by the U.S. Department of Health and Human Services.

“After assessing all available preclinical, clinical, and epidemiological data, FDA recommends that marijuana be rescheduled from Schedule I into Schedule III of the CSA,” the documents said.

“Schedule III drugs are classified as having a potential for abuse less than the drugs or other substances in schedules I and II, a currently accepted medical use in treatment in the United States, and moderate or low physical dependence or high psychological dependence that may result from their use. NIDA [National Institute on Drug Abuse] concurs with this recommendation.”

Transitioning from Schedule I to Schedule III would reposition marijuana from the same classification as heroin and LSD to the category that includes substances like anabolic steroids and ketamine.

While the DEA has yet to act on this recommendation, it has the potential to ignite a new era for the cannabis industry.

The industry is already flourishing. According to Grand View Research, the U.S. cannabis market was valued at $13.2 billion in 2022. Moreover, this figure is expected to continue its upward trajectory at a compound annual growth rate of 14.2% from 2023 to 2030.

What to read next

About the Author

Jing Pan

Jing Pan

Investment Reporter

Jing is an investment reporter for MoneyWise. He is an avid advocate of investing for passive income. Despite the ups and downs he’s been through with the markets, Jing believes that you can generate a steadily increasing income stream by investing in high quality companies.

What to Read Next


The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.